TY - JOUR
T1 - Recent clinical trials in the rheumatic diseases
AU - Matteson, Eric L.
PY - 1997
Y1 - 1997
N2 - This paper reviews clinical trials that have been published during the course of the past year on the rheumatologic diseases. The greatest number of clinical trials were done in rheumatoid arthritis. These trials show promising results for combination therapy with disease-modifying antirheumatic drugs, whereas results of studies with monoclonal antilymphocyte antibodies have been disappointing. The role of oral collagen remains to be defined. Nonsteroidal anti-inflammatory drugs with selective cyclooxygenase-2 (Cox-2) inhibition may have a more favorable toxicity profile and are likely to find wide use. As adjuvant therapy, trimethoprim-sulfamethoxazole appears to be useful in preventing relapses in Wegener's granulomatosis, and patients develop fewer infections. With the exception of juvenile rheumatoid arthritis, intravenous immunoglobulin therapy appeared ineffective in the diseases studied. The inclusion of more standardized and disease-specific outcome measures has enhanced the quality of clinical trials in rheumatology and their applicability to rheumatologic practice.
AB - This paper reviews clinical trials that have been published during the course of the past year on the rheumatologic diseases. The greatest number of clinical trials were done in rheumatoid arthritis. These trials show promising results for combination therapy with disease-modifying antirheumatic drugs, whereas results of studies with monoclonal antilymphocyte antibodies have been disappointing. The role of oral collagen remains to be defined. Nonsteroidal anti-inflammatory drugs with selective cyclooxygenase-2 (Cox-2) inhibition may have a more favorable toxicity profile and are likely to find wide use. As adjuvant therapy, trimethoprim-sulfamethoxazole appears to be useful in preventing relapses in Wegener's granulomatosis, and patients develop fewer infections. With the exception of juvenile rheumatoid arthritis, intravenous immunoglobulin therapy appeared ineffective in the diseases studied. The inclusion of more standardized and disease-specific outcome measures has enhanced the quality of clinical trials in rheumatology and their applicability to rheumatologic practice.
UR - http://www.scopus.com/inward/record.url?scp=0030919364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030919364&partnerID=8YFLogxK
U2 - 10.1097/00002281-199703000-00003
DO - 10.1097/00002281-199703000-00003
M3 - Short survey
C2 - 9135911
AN - SCOPUS:0030919364
SN - 1040-8711
VL - 9
SP - 95
EP - 101
JO - Current opinion in rheumatology
JF - Current opinion in rheumatology
IS - 2
ER -